Research graph
References from Metabolomic Signatures of Inflammation in Chronic Kidney Disease. Local targets link to admitted publications; unresolved targets remain external evidence.
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
10.1038/s41581-022-00621-9 · 2022 · External reference
Inflammation and progression of CKD: the CRIC Study
10.2215/cjn.13121215 · 2016 · External reference
Plasma biomarkers of tubular injury and inflammation are associated with CKD progression in children
10.1681/asn.2019070723 · 2020 · External reference
Associations of plasma biomarkers of inflammation, fibrosis, and kidney tubular injury with progression of diabetic kidney disease: a cohort study
10.1053/j.ajkd.2021.09.018 · 2022 · External reference
Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study
10.1093/eurjpc/zwad197 · 2023 · External reference
Inflammation in heart failure: JACC state-of-the-art review
10.1016/j.jacc.2020.01.014 · 2020 · External reference
The immunology of atherosclerosis
10.1038/nrneph.2017.51 · 2017 · External reference
Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients
10.1681/asn.v13suppl_1s28 · 2002 · External reference
Biomarkers of immune activation and incident kidney failure with replacement therapy: findings from the African American Study of Kidney Disease and Hypertension
10.1053/j.ajkd.2020.11.014 · 2021 · External reference
Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality
10.1093/ndt/gfaa260 · 2021 · External reference
Longitudinal TNFR1 and TNFR2 and kidney outcomes: results from AASK and VA NEPHRON-D
10.1681/asn.2021060735 · 2022 · External reference
Associations of baseline and longitudinal serum uromodulin with kidney failure and mortality: results from the African American Study of Kidney Disease and Hypertension (AASK) trial
10.1053/j.ajkd.2023.05.017 · 2024 · External reference
Comparison of aptamer-based and antibody-based assays for protein quantification in chronic kidney disease
10.2215/cjn.11700921 · 2022 · External reference
Proteins associated with risk of kidney function decline in the general population
10.1681/asn.2020111607 · 2021 · External reference
Multiple loci associated with indices of renal function and chronic kidney disease
10.1038/ng.377 · 2009 · External reference
The associations of plasma biomarkers of inflammation with histopathologic lesions, kidney disease progression, and mortality-the Boston Kidney Biopsy Cohort study
10.1016/j.ekir.2020.12.025 · 2021 · External reference
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
10.1001/jama.288.19.2421 · 2002 · External reference
Intensive blood-pressure control in hypertensive chronic kidney disease
10.1056/nejmoa0910975 · 2010 · External reference
The Atherosclerosis Risk in Communities (ARIC) study: design and objectives
10.1093/oxfordjournals.aje.a115184 · 1989 · External reference
The prognostic value of histopathologic lesions in native kidney biopsy specimens: results from the Boston Kidney Biopsy Cohort study
10.1681/asn.2017121260 · 2018 · External reference
NAT8 variants, N-acetylated amino acids, and progression of CKD
10.2215/cjn.08600520 · 2020 · External reference
Serum and urine metabolites and kidney function
10.1681/asn.0000000000000403 · 2024 · External reference
Circulating protein and metabolite correlates of histologically confirmed diabetic kidney disease
10.1016/j.xkme.2024.100920 · 2024 · External reference
APOL1 kidney risk variants and proteomics
10.2215/cjn.14701121 · 2022 · External reference
Analytical and biological variability of a commercial modified aptamer assay in plasma samples of patients with chronic kidney disease
10.1093/jalm/jfac145 · 2023 · External reference
New creatinine- and cystatin C-based equations to estimate GFR without race
10.1056/nejmoa2102953 · 2021 · External reference
Proteomics and incident kidney failure in individuals with CKD: the African American Study of Kidney Disease and Hypertension and the Boston Kidney Biopsy Cohort
10.1016/j.xkme.2024.100921 · 2024 · External reference
The artificial sweetener erythritol and cardiovascular event risk
10.1038/s41591-023-02223-9 · 2023 · External reference
Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study
10.1681/asn.2020040487 · 2021 · External reference
Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study
10.1053/j.ajkd.2018.09.012 · 2019 · External reference
Immune and inflammatory mechanisms in hypertension
10.1038/s41569-023-00964-1 · 2024 · External reference
The role of interferon-gamma in cardiovascular disease: an update
10.1007/s00011-020-01382-6 · 2020 · External reference
Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease
10.1161/circresaha.121.319077 · 2021 · External reference
Interleukin-6 and cardiovascular events in healthy adults: MESA
10.1016/j.jacadv.2024.101063 · 2024 · External reference
Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA)
10.1053/j.ajkd.2012.02.335 · 2012 · External reference
Association of IL-8 with infarct size and clinical outcomes in patients with STEMI
10.1016/j.jacc.2018.04.053 · 2018 · External reference
The relationship between IL-10 levels and cardiovascular events in patients with CKD
10.2215/cjn.08660813 · 2014 · External reference
Serum uromodulin and mortality risk in patients undergoing coronary angiography
10.1681/asn.2016111162 · 2017 · External reference
Association of serum uromodulin with mortality and cardiovascular disease in the elderly-the Cardiovascular Health Study
10.1093/ndt/gfz008 · 2020 · External reference
Serum uromodulin: a biomarker of long-term kidney allograft failure
10.1159/000489095 · 2018 · External reference
Urine epidermal growth factor and kidney function decline in middle-aged adults
10.1016/j.xkme.2024.100846 · 2024 · External reference
Associations of urine epidermal growth factor with kidney and cardiovascular outcomes in individuals with CKD in SPRINT
10.1016/j.ekir.2024.08.004 · 2024 · External reference
Synergistic transcriptional activation of indoleamine dioxygenase by IFN-γ and tumor necrosis factor-α
10.1089/107999003322277829 · 2003 · External reference
Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced antichlamydial indoleamine dioxygenase activity independently
10.1089/107999000312306 · 2000 · External reference
Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells
10.1006/cyto.1999.0661 · 2000 · External reference
IDO expression by dendritic cells: tolerance and tryptophan catabolism
10.1038/nri1457 · 2004 · External reference
Metabolites associate with kidney function decline and incident chronic kidney disease in the general population
10.1093/ndt/gft217 · 2013 · External reference
Plasma tryptophan-kynurenine pathway metabolites and risk for progression to end-stage kidney disease in patients with type 2 diabetes
10.2337/dc23-1147 · 2023 · External reference
The association of serum carotenoids, tocopherols, and ascorbic acid with rapid kidney function decline: the Coronary Artery Risk Development in Young Adults (CARDIA) study
10.1053/j.jrn.2018.05.008 · 2019 · External reference
Effects of diet and sodium reduction on cardiac injury, strain, and inflammation: the DASH-Sodium trial
10.1016/j.jacc.2021.03.320 · 2021 · External reference
Effects of the Dietary Approaches to Stop Hypertension diet on change in cardiac biomarkers over time: results from the DASH-Sodium trial
10.1161/jaha.122.026684 · 2023 · External reference
Identification of protein biomarkers of the Dietary Approaches to Stop Hypertension diet in randomized feeding studies and validation in an observational study
10.1161/jaha.122.028821 · 2023 · External reference
Twelve-week Mediterranean diet intervention increases citrus bioflavonoid levels and reduces inflammation in people with type 2 diabetes mellitus
10.3390/nu13041133 · 2021 · External reference
Adherence to the mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study
10.1161/circulationaha.107.710699 · 2008 · External reference
A clinical trial of the effects of dietary patterns on blood pressure
10.1056/nejm199704173361601 · 1997 · External reference
DASH (Dietary Approaches to Stop Hypertension) diet and risk of subsequent kidney disease
10.1053/j.ajkd.2016.05.019 · 2016 · External reference
Adherence to healthy dietary patterns and risk of CKD progression and all-cause mortality: findings from the CRIC (Chronic Renal Insufficiency Cohort) study
10.1053/j.ajkd.2020.04.019 · 2021 · External reference
Mediterranean diet adherence and risk of all-cause mortality in women
10.1001/jamanetworkopen.2024.14322 · 2024 · External reference
Mediterranean diet, kidney function, and mortality in men with CKD
10.2215/cjn.01780213 · 2013 · External reference
Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts
10.1056/nejmoa1800389 · 2018 · External reference
IL8 and IL16 levels indicate serum and plasma quality
10.1515/cclm-2017-1047 · 2018 · External reference
Association of a biomarker of glucose peaks, 1,5-anhydroglucitol, with subclinical cardiovascular disease
10.2337/dc16-0840 · 2016 · External reference
Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial
10.1111/dom.13755 · 2019 · External reference
Association of 1,5-anhydroglucitol with cardiovascular disease and mortality
10.2337/db15-0607 · 2016 · External reference
Effects of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: results from the OmniCarb trial
10.1111/dme.13391 · 2017 · External reference
Circulating metabolites improve the prediction of renal impairment in patients with type 2 diabetes
10.1136/bmjdrc-2023-003422 · 2023 · External reference
Novel findings from a metabolomics study of left ventricular diastolic function: the Bogalusa Heart Study
10.1161/jaha.119.015118 · 2020 · External reference
